Intradialytic Administration of Amphotericin B: Clinical Observations on Efficacy and Safety-Reference-Cited by-同舟云学术

Intradialytic Administration of Amphotericin B: Clinical Observations on Efficacy and Safety

Published:2004-01 Issue:1 Volume:327 Page:5-8
ISSN:0002-9629
Container-title:The American Journal of the Medical Sciences
language:en
Short-container-title:The American Journal of the Medical Sciences

Author:

Wood James E.,Mahnensmith Mary P.,Mahnensmith Rex L.,Perazella Mark A.

Publisher

Elsevier BV

Subject

General Medicine

Reference17 articles.

1. Therapy with amphotericin B of candida septicemia in the presence of acute renal failure;Richardson;Invest Urology,1968

2. A pharmacologic guide to the clinical use of amphotericin B;Bindschadler;J Infect Dis,1969

3. Antifungal agents. Part I. Amphotericin B preparations and flucytosine;Patel;Mayo Clin Proc,1998

4. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B;Gigliotti;J Infect Dis,1987

5. Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1 [abstract];Gelfand;Clin Res,1988

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India;The Lancet Infectious Diseases;2022-09

2. A Case-Control Study on Mucormycosis in Tertiary Care Hospital, Bhopal;Indian Journal of Community Medicine;2022-07

3. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature;Mycopathologia;2021-02-05

4. Clinical Pharmacokinetics of Systemically Administered Antimycotics;Current Clinical Pharmacology;2007-01-01